Overview

Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Chiron Corporation
Treatments:
Fluorouracil
Tezacitabine